Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vandetanib
Vandetanib and Etoposide · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Vandetanib and Etoposide | EXPERIMENTAL | Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide. |
| Name | Type | Description |
|---|---|---|
| Vandetanib and Etoposide | DRUG | Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle. |
Inclusion Criteria: Patients have baseline evaluations ≤14days prior to 1st dose of study drug unless otherwise specified * Patients with confirmed malignant glioma (MG) who are recurrence/relapse * Patients may not have stereotactic tumor biopsy \< 1 week or surgical resection or open biopsy \< 4...
Vandetanib is an investigational small molecule being studied in oncology for anal, colon, and rectal cancers, gliosarcoma, and transitional cell carcinoma. It is a kinase inhibitor in Phase 1 clinical development. Vandetanib is not approved and remains under investigation for these indications.
Vandetanib is a kinase inhibitor, belonging to the -nib class of drugs that block specific enzymes involved in cancer cell growth. It is being studied for its effects on tumors in anal, colon, and rectal cancers, gliosarcoma, and transitional cell carcinoma, though its precise molecular targets are not specified.
Vandetanib is being developed by AstraZeneca PLC, a company traded under the ticker AZN. The drug is an investigational small molecule in Phase 1 clinical development for multiple oncology indications, including anal, colon, and rectal cancers, gliosarcoma, and transitional cell carcinoma.
Vandetanib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed for its studied indications, including a Phase 1 trial for metastatic colorectal cancer and a Phase 2 trial for transitional cell carcinoma.
Vandetanib has been studied in clinical trials including NCT00532909, a Phase 1 trial combining Vandetanib with capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer, and NCT00613223, a Phase 1 dose escalation trial with etoposide for malignant gliomas. NCT00880334 was a Phase 2 randomized study of docetaxel with or without Vandetanib in metastatic transitional cell carcinoma.
Vandetanib is a distinct investigational kinase inhibitor developed by AstraZeneca. It is not known to be the same as any other drug. Its development focuses on anal, colon, and rectal cancers, gliosarcoma, and transitional cell carcinoma, with completed trials showing it is still in early clinical phases.